Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors.

European journal of cancer (Oxford, England : 1990) - 1 May 2021

Kato Shumei, Porter Robert, Okamura Ryosuke, Lee Suzanna, Zelichov Ori, Tarcic Gabi, Vidne Michael, Kurzrock Razelle

Abstract excerpt

BACKGROUND: RAS variant-related functional impact on the mitogen-activated protein kinase (MAPK) pathway, and correlation between MAPK activation and MAPK/ERK kinase (MEK) inhibitor responsiveness, is not established. PATIENTS AND METHODS: Of 1,693 tumours sequenced, 576 harboured a RAS alteration; 62 patients received an MEK inhibitor (MEKi) and had RAS mutations that were functionally characterised. We report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to Mitogen-Activated Protein Kinases

Share to Neoplasms

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Time Factors

Source

Identifiers

PMID: 33865203
DOI: 10.1016/j.ejca.2021.01.055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors.PMID 33865203Read ↗

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read ↗

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancersSemantic proximity Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.Semantic proximity Read ↗

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.Semantic proximity Read ↗

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid CancersSemantic proximity Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.Semantic proximity Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.Semantic proximity Read ↗

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.